Triple-Drug cocktail targets Hard-to-Treat cancers
NCT ID NCT03842228
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patients with specific genetic mutations in their tumors are eligible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Copanlisib, olaparib, and durvalumab
- What this could lead to
- If this works, it could point toward a new treatment option for people with advanced solid tumors that have specific genetic mutations.
- What could go wrong
- This is a very early (Phase 1) and small trial (39 people), so it's mainly checking safety and dosing. The combination may cause significant side effects and may not shrink tumors in most patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Keck Medical Center of USC Pasadena
Pasadena, California, 91105, United States
-
Keck Medicine of USC Buena Park
Buena Park, California, 90621, United States
-
Keck Medicine of USC Koreatown
Los Angeles, California, 90020, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California, 92663, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229, United States
-
University of Texas Medical Branch
Galveston, Texas, 77555-0565, United States
-
University of Texas at Austin
Austin, Texas, 78712, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?